I

Incyte Corp
D

INCY

70.000
USD
0.92
(1.33%)
مغلق
حجم التداول
137,936
الربح لكل سهم
6
العائد الربحي
-
P/E
467
حجم السوق
13,546,704,500
أصول ذات صلة
    ABBV
    ABBV
    0.400
    (0.21%)
    193.450 USD
    AMGN
    AMGN
    1.75
    (0.59%)
    296.86 USD
    BMY
    BMY
    -0.185
    (-0.33%)
    55.960 USD
    GILD
    GILD
    2.580
    (2.50%)
    105.940 USD
    MRK
    MRK
    -1.240
    (-1.45%)
    84.440 USD
    REGN
    REGN
    10.02
    (1.51%)
    673.66 USD
    VRTX
    VRTX
    9.28
    (2.05%)
    462.59 USD
    المزيد
الأخبار المقالات

العنوان: Incyte Corp

القطاع: Healthcare
الصناعة: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.